** Shares of U.S. drugmaker Eli Lilly LLY.N rise 2.11% to $900.01 premarket
** The company says it has begun selling vials of higher dosages of its popular weight-loss drug Zepbound, which is typically sold in auto-injector pens, in the U.S.
** The vials are priced at a $150 discount to the cost of the injector pen version
** Says patients can purchase 7.5 mg and 10mg vials of Zepbound for $499 a month on from its B2C LillyDirect website
** Last August, co launched two lower dose vials of Zepbound to help increase availability
** Says it had reduced prices for a month's supply of lower dosage vials by around $50
** LLY rose 14.5% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。